Specific delivery of captopril to the kidney with the prodrug captopril- lysozyme

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 281-285

  Kok, R J ^a,c   Grijpstra, F ^a   Walthuis, R B ^a   Moolenaar, F ^a   De Zeeuw, D ^b   Meijer, D K F ^a  

^a Utrecht Inst Drug Explor   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LYSOZYME;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; KIDNEY CLEARANCE; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; DRUG DELIVERY SYSTEMS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MURAMIDASE; PRODRUGS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 0032939450     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Atassi MZ and Habeeb AF (1969) Enzymic and immunochemical properties of lysozyme. I. Derivatives modified at tyrosine: Influence of nature of modification on activity. Biochemistry 8:1385-1393.
2. Cushman DW, Wang FL, Fung WC, Grover GJ, Harvey CM, Scalese RJ, Mitch SL and DeForrest JM (1989) Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 28 (Suppl 2):115S-130S.
3. Franssen EJF, Van Amsterdam RGM, Visser J, Moolenaar F, De Zeeuw D and Meijer DKF (1991) Low molecular weight proteins as carriers for renal drug targeting, naproxen-lysozyme. Pharm Res 8:1223-1230.
4. Franssen EJF, Moolenaar F, De Zeeuw D and Meijer DKF (1994) Drug targeting to the kidney with low-molecular-weight proteins. Adv Drug Dev Rev 14:67-88.
5. Haas M, Meijer DKF, Moolenaar F, De Jong PE and De Zeeuw D (1996) Renal drug targeting: Optimalisation of renal pharmacotherapeutics, in International Yearbook of Nephrology 1996 (Andreucci VE and Fine LG eds) pp 3-11, Oxford University Press, New York.
6. Hysing J and Tolleshaug H (1986) Quantitative aspects of the uptake and degradation of lysozyme in the rat kidney in vivo. Biochim Biophys Acta 887:42-50.
7. Koiter J, Navis G, De Jong PE, van Gilst WH and De Zeeuw D (1998) Sample dilution: A methodological pitfall in measurements of tissue but not serum ACE activity. J Pharmacol Toxicol Methods 39:45-49.
8. Kok RJ, Visser J, Moolenaar F, De Zeeuw D and Meijer DKF (1997) Bioanalysis of captopril: Two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. J Chromatogr B Biomed Appl 693:181-189.
9. Maack T, Johnson V, Kau ST, Figuereido J and Sigulem D (1979) Renal filtration, transport and metabolism of low molecular weight proteins: A review. Kidney Int 16:251-270.
10. Matsumoto K, Miyazaki H, Fujii T, Yoshida K, Amejima H and Hashimoto M (1986) Disposition and metabolism of the novel antihypertensive agent alacepril in rats. Arzneimittelforschung 1:40-46.
11. Navis G, Faber HJ, De Zeeuw D and De Jong PE (1996) ACE inhibitors and the kidney: A risk-benefit assessment. Drug Safety 15:200-211.
12. Ondetti MA and Cushman DW (1981) Inhibition of the renin-angiotensin system: A new approach to the therapy of hypertension. J Med Chem 24:355-361.
13. 14C]captopril to plasma proteins in the rat. Biochem Pharmacol 31:1755-1760.
14. Steffens AB (1969) A method for frequent sampling of blood and continuous infusion of fluids without disturbing the animal. Physiol Behav 4:833-836.